Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study
HIV medicine, 2026
A Novel Microfluidic Strategy for the Fabrication of α-Lactalbumin Nanomicelles Paves a New Path for Antiobesity Technology
Advanced healthcare materials, 2026;:e71486
Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes
British journal of clinical pharmacology, 2026
Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults
Diabetes, obesity & metabolism, 2026
Comment on “Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes”
Medicina clinica, 2026;166(10):107573
Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine
Journal of cardiovascular pharmacology, 2026
Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review
Therapeutic advances in endocrinology and metabolism, 2026;17:20420188261469947
Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations
International clinical psychopharmacology, 2026
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
Frontiers in pharmacology, 2026;17:1917800
Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment
Frontiers in endocrinology, 2026;17:1819337
Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase)
BMC pharmacology & toxicology, 2026;27(1)
Accidental intradermal injection of tirzepatide associated with increased adverse events
Postgraduate medical journal, 2026
Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination – The REST trial study protocol
PloS one, 2026;21(7):e0354237
Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026
Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis
Journal of clinical psychopharmacology, 2026
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025
British journal of clinical pharmacology, 2026
The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany
Cost effectiveness and resource allocation : C/E, 2026;24(1)
“Examining the Impact of Perioperative Glucagon-Like-Peptide-1 use within Foot and Ankle Surgery: A Systematic Review of Comparative Studies”
The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons, 2026
GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period
Appetite, 2026;:108729
GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
Therapeutic advances in endocrinology and metabolism, 2026;17:20420188261472587